Auditory dysfunction is related to large/small vessel occlusions and hemorrhage. Sudden sensorineural hearing loss (SSNHL) frequently occurs with anterior inferior cerebellar artery occlusion proximal to the internal auditory artery. Moreover, SSNHL has various pathogenetic mechanisms, the main proposed mechanisms being vascular disease, membrane ruptures, infection, and autoimmunity. Tumor necrosis factor (TNF) is an important cytokine in the inflammation process of cerebrovascular diseases. In the current study, the possible effects of polymorphisms in TNF-a and TNF-b genes on SSNHL are evaluated. Two genetic polymorphisms in the TNF locus (TNF-a -308 G -->A and TNF-b þ252 A -->G) were investigated as risk factors for SSNHL by determining their prevalence in 97 SSNHL patients and in 587 controls. A significant increase was found for the TNF-b allele 1 in SSNHL patients compared with the controls (w 2 ¼ 7.251, P ¼ .007, odds ratio [OR] ¼ 1.534, confidence interval [CI] ¼ 1.12-2.10). These findings suggest that the TNF-b þ252 locus plays an important role in the etiopathogenesis of SSNHL.
Introduction
Sudden sensorineural hearing loss (SSNHL) is defined as a sensorineural hearing loss of 30 dB or more over at least 3 contiguous audiometric frequencies that develops over a period of a few hours to 3 days. 1 Many hypotheses for SSNHL have been advanced to explain its etiology, including viral inflammation, vascular occlusive disease, allergic reactions, rupture of the intralabyrinthine membranes, local histamine production, and autoimmune disease. 2, 3 However, in the majority of cases, the cause of the pathology is not clear.
The auditory symptoms associated with brain stem stroke include hearing loss, phantom auditory perceptions, and hyperacusis. These may be associated with widespread ischemia due to vertebrovascular occlusive disease or a large hemorrhage or with focal disease due to a penetrating artery occlusion or a small hemorrhage. 4 In particular, tinnitus and hearing loss can occur with vertebrabasilar disease. A sudden onset of unilateral or bilateral deafness, usually accompanied by dizziness or vertigo, can be a sign of basilar artery occlusive disease. 4 Since a study in 1962 in which it was reported that patients with basilar insufficiency suffered hearing impairment, 5 the rate of auditory dysfunction in conjunction with stroke has gradually increased. In 2001, Yamasoba et al reported that 15 patients (21%) among 70 vertiginous patients with vertebrobasilar insufficiency experienced acute hearing impairment with vertigo. 6 Tumor necrosis factor (TNF) is an important cytokine in the inflammation process of cerebrovascular and other diseases. Several studies have implicated TNF gene variants as risk factors for stroke, including cerebral infarction. [7] [8] [9] [10] [11] However, the role of TNF variants in auditory dysfunction is largely unknown. The purpose of the current study was to investigate the possible effects of TNF variants (TNF-a -308 G -->A and TNF-b þ252 A -->G) in SSNHL.
Materials and Methods Participants
Ninety-seven consecutive patients with SSNHL (63 males and 34 females, mean age: 48.3 + 17.2) participated in this study. Hearing loss patients with recent viral infections such as upper respiratory infection or syphilis or a history of venous thrombosis or neurological diseases were excluded from the study. The patients also showed a normal range of erythrocyte sedimentation and C-reactive protein. The day of initial presentation ranged between the 1st and 18th days (average 4.25 days) after the acute onset of SSNHL. The hearing loss in all of these patients was sudden, meaning that it had occurred within 3 days or less. Pure tone audiometry, speech audiometry, and auditory brain stem response were recorded in every patient. A hearing loss of 30 dB or greater in at least 3 contiguous frequencies formed the audiometric inclusion criterion. All patients were admitted to the hospital within 2 weeks after the onset of SSNHL. The control group (mean age: 62.2 + 9.8, male 48.2%, n ¼ 537) included individuals without a family history of thrombosis and SSNHL.
Genotyping of TNF Polymorphisms
Genomic DNA was extracted via an inorganic procedure. 12 A single base pair polymorphism at position -308 in the promoter region of the TNF-a gene was examined by the NcoI (Takara, Shiga, Japan) restriction fragment length polymorphism (RFLP) method, as described in the literature. 13 The following primers for TNF-a were used: 5 0 -AGGCAATAGGTTTT-GAGGGCCAT-3 0 and 5 0 -TCCTCCCTGCTCCGATTCCG-3 0 . For identification of the TNF-b þ252 polymorphism, NcoI restriction enzyme digestion was used after PCR amplification to define the TNF-b genotypes. The following primers were used: 5 0 -CCGTGCTTCGTGCTTTGGACTA-3 0 and 5 0 -AGAGCTGGTGGGACATGTCTG-3 0 . A 740-bp fragment amplified across intron 2 of the TNF-b gene incorporates a polymorphic NcoI site, which generates products of 555 and 185 bp for allele 1 (A1, the 5.5-kb allele) and 740 bp for allele 2 (A2, the 10-kb allele). Details regarding the PCR and restriction-digestion protocols have been reported elsewhere. 13 
Statistical Analysis
A w 2 test was used to compare genotype and allele frequencies between the SSNHL and control populations. Odds ratios (ORs) were calculated with 95% confidence intervals (CI). All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) v12.00 (SPSS Inc) statistical analysis software. A P value of less than .05 was considered statistically significant.
Results
Tables 1 and 2 display the distribution of genotypes for TNF-a and TNF-b. The genotype frequencies for TNF polymorphisms were in Hardy-Weinberg equilibrium. No significant differences in the allele and genotype frequencies of the TNF-a-308G/A polymorphism were found between SSHNL patients and controls (Table 1) . For the TNF-b þ252 locus, the distribution of the genotype in 97 SSNHL patients was as follows: A1A1, 28 (30.4%); A1A2, 46 (50.0%); and A2A2, 18 (19.6%). This was significantly different from the distribution in the 587 control participants: A1A1, 108 (18.8%); A1A2, 298 (51.9%); and A2A2, 168 (29.3%; w 2 ¼ 7.972, P ¼ 0.019). The frequency of allele 1 carriers (A1A1/A1A2) was higher in SSNHL patients (80.4%) than in controls (70.7%), although the statistical significance was marginal (w 2 ¼ 3.709, P ¼ .056, OR ¼ 1.701, CI ¼ 0.986-2.936). Furthermore, the difference was more apparent in the allele frequencies between SSNHL patients and controls. The allele frequencies of SSNHL patients were A1, 102 (55.4%), and A2, 82 (44.6%); this distribution was significantly different from that of the controls: A1, 514 (44.8%); and A 2, 634 (55.2%; w 2 ¼ 7.251, P ¼ .007, OR ¼ 1.534, CI ¼ 1.12-2.10; Table 2 ).
Discussion
Sudden deafness is one of the sequelae from stroke and can negatively affect the outcome of this affliction. Stroke patients do not typically complain of hearing problems. In many cases, hearing complaints are overshadowed by complaints that are more serious involving other neurological systems. 4 However, it is important that neurologists recognize sudden deafness of a vascular cause, as the management and prognosis generally differ from those of hearing loss associated with viral inflammation. Although hearing loss itself is not life-threatening, hearing loss due to a vascular cause may be life-threatening as it sometimes appears as a warning sign of impending vertebrobasilar ischemic stroke. [14] [15] [16] Vascular disorders may cause SSNHL due to a cochlear injury. Notably, a number of studies regarding the relationship between SSNHL and thrombosis, a common risk factor in vascular diseases, have been reported. [17] [18] [19] [20] Endothelial nitric oxide synthase and glutathione S-transferase gene polymorphisms were evaluated in the pathogenesis of SSNHL, as well as prothrombotic risk factors including methylenetetrahydrofolate reductase (MTHFR), prothrombin, factor V, plasminogen activator inhibitor-1, and endothelial cell protein C receptor (EPCR). [20] [21] [22] Yildiz et al reported that the EPCR 23-bp insertion was 0% in controls and was found in 3 SSNHL patients (3.7%). 20 The current study is the first study to evaluate the possible role of TNF polymorphism in SSNHL.
Tumor necrosis factor is one of the most potent inflammatory cytokines. Inflammation is a well-established risk factor for vascular disease and may play critical roles in the pathology of SSNHL. Hearing loss is typically treated with drugs that provide better blood supply to the inner ear and decrease inflammation. 23 Lorenz et al reported that autoimmune sensorineural hearing loss patients often have a high frequency of circulating proinflammatory T helper T cells specific for inner ear antigens. 24 They suggest that inner ear-specific interferon-g producing proinflammatory T cells play a key role in the pathogenesis of autoimmune sensorineural hearing loss. 24 Additionally, Adams reported that several inflammatory cytokines are expressed in cochlea tissue. 25 In the current study, polymorphisms in the TNF-a and TNFb genes were assessed for evidence of association with SSNHL. From this assessment, a significant difference was observed between SSNHL and controls in participants with the TNF-b þ252 allele 1. This suggests that the TNF-b þ252 locus plays an important role in the etiopathogenesis of SSNHL. Further studies are needed to address the molecular mechanisms by which the TNF gene is involved in the development of SSNHL. 
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